feedback

Course Director

Farhad Ravandi, MD
Farhad Ravandi, MD

The University of Texas MD Anderson Cancer Center
Houston, Texas

Faculty

Jessica K. Altman
Jessica K. Altman, MD

Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

Naval Daver
Naval Daver, MD

The University of Texas MD Anderson Cancer Center
Houston, Texas

Amir T. Fathi
Amir T. Fathi, MD

Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:2.0 Credits
Release Date:2018-Jul-03
Expiration Date:2019-Jul-02
Estimated Time for Completion:120 minutes
Registration Required:No
Cost:Free of charge

Activity Description and Educational Objectives

In this activity based on a live symposium held in Chicago, experts in AML discuss the practicalities of population-based AML treatment with a focus on how new research can be applied to clinical practice.

Upon completion of this activity, participants should be better able to:
  • Cite baseline factors, including age, functional status, antecedent hematologic disorders, therapy-related disease, cytogenetic and mutational findings, among others, that may influence treatment decisions in acute myeloid leukemia (AML)
  • Summarize updated evidence on the efficacy of novel cytotoxic, targeted, epigenetic, and antibody-based strategies in a range of AML patient populations
  • Recommend individualized therapy for patients with AML after considering relevant prognostic and other baseline features
  • Manage treatment-related adverse events in patients with AML on therapy with regimens containing novel components

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, hematologist-oncologists, and other clinicians involved in the management of AML.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: July 03, 2018 - July 02, 2019
Time to Complete: 120 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director and Moderator

Farhad Ravandi, MD
Janiece and Stephen A. Lasher Professor of Medicine
Chief, Section of Developmental Therapeutics
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Farhad Ravandi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Amgen Inc.; Astellas Pharma US, Inc.; MacroGenics, Inc.; and Orsenix.
Grant/Research Support from Amgen Inc.; Bristol-Myers Squibb; MacroGenics, Inc.; Orsenix; Seattle Genetics, Inc.; Selvita; and Xencor.
Other Financial or Material Support from CME Events for AbbVie Inc.; Agios, Inc.; and Takeda Pharmaceutical Company Limited.

Farhad Ravandi, MD, does not intend to discuss any non–FDA-approved or investigational use of any products/devices.

Faculty

Jessica K. Altman, MD
Director, Acute Leukemia Program
Associate Professor of Medicine
Robert H. Lurie Comprehensive Cancer Center
Division of Hematology/Oncology
Northwestern University
Chicago, Illinois

Jessica K. Altman, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board for Astellas.

Jessica K. Altman, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: FLT3 inhibitors in the management of various AML populations.

Naval Daver, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Naval Daver, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Incyte Corporation; Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; and Sunesis Pharmaceuticals, Inc.
Grant/Research Support from Bristol-Myers Squibb; Incyte Corporation; Kiromic; Pfizer Inc.; and Sunesis Pharmaceuticals, Inc.

Naval Daver, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: Immune checkpoint inhibitors, targeted therapies such as Bcl-2 inhibitors, and novel antibodies in the management of various AML populations.

Amir T. Fathi, MD
Director of Leukemia
Massachusetts General Hospital Cancer Center
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Amir T. Fathi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Celgene Corporation; Seattle Genetics, Inc.; and Takeda Pharmaceutical Company Limited.
Advisory Board for Agios, Inc.; Astellas Pharma US, Inc.; Jazz Pharmaceuticals Inc.; and Pfizer Inc.

Amir T. Fathi, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: IDH 1/2 inhibitors in the management of various AML populations.

CME Reviewer

Siyang Leng, MD

Siyang Leng, MD, has no financial interests/relationships or affiliations in relation to this activity.

Medical Directors

Kathryn B. Charalambous, PhD
PVI, PeerView Institute for Medical Education

Kathryn B. Charalambous, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership



This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by independent educational grants from AbbVie, Astellas, Celgene Corporation, Daiichi Sankyo, Inc., and Jazz Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.